Oncology Medical News

Become a Member Today!
Register

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. Recommendations on the use of 18F-FDG PET in oncology

3. Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials

4. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer

5. Sentinel node biopsy is important in mastectomy for ductal carcinoma in situ

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Nuclear factor-kappa B pathway and response in a phase II trial of bortezomib and docetaxel in patients with recurrent and/or metastatic head and neck squamous cell carcinoma
Annals of Oncology, 10/28/09

Chung CH et al. – Further understanding of treatment resistance and interactions between bortezomib and docetaxel may provide novel approaches in managing HNSCC.

Methods

Patients with recurrent and/or metastatic HNSCC enrolled on phase II bortezomib/docetaxel trial (bortezomib 1.6 mg/m2 and docetaxel 40 mg/m2 on days 1 and 8 of a 21-day cycle)
Response assessed using RECIST
Tissue specimens evaluated for presence of HPV and expression of NF-B-associated genes

Results

21 of 25 enrolled patients were assessable for response; one partial response , 10 stable disease and 10 progressive disease
Patients with PR/SD had significantly longer survival compared with patients with PD and regimen was well tolerated
Only 1 of 20 tumors was positive for HPV
Patients with PD had higher expression of NF-B and epidermal growth factor receptor-associated genes in their tumors by gene expression analysis

<< Previous
Colorectal cancer incidence and postmenopausal hormone use by...

Next >>
Molecular markers associated with lymph node metastasis in...